High-grade B-cell Lymphoma Not Otherwise Specified

• CLINICAL_TRIALS trial_result · 2025-01-29
  Clinical Trial Update: Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma [Phase 1]

  A Phase 1 trial evaluating the combination of chemotherapy with TAK-659 as front-line treatment for high-risk diffuse large B-cell lymphoma,…

• CLINICAL_TRIALS trial_result · 2021-12-21
  Clinical Trial Update: Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]

  Phase 3 clinical trial update investigating zanubrutinib with rituximab and/or combination chemotherapy for newly diagnosed aggressive B-cel…

• CLINICAL_TRIALS trial_result · 2021-11-19
  Clinical Trial Update: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]

  Phase 3 trial update evaluating orelabrutinib with rituximab and combination chemotherapy for newly diagnosed aggressive B-cell non-Hodgkin …

• CLINICAL_TRIALS trial_result · 2018-03-27
  Clinical Trial Update: R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS) [Phase 3]

  Phase 3 clinical trial comparing R-BL-M-04 to Rituximab plus DA-EPOCH with autologous stem cell transplantation in high-grade B-cell lymphom…